Revolution Medicines, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M | $43.0M | $50.0M | $20.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M | $132.3M | $91.8M | $51.1M |
| SG&A Expense | $195.0M | $97.3M | $75.6M | $40.6M | $30.5M | $21.4M | $12.4M | $9.4M |
| Operating Income | $-1.18B | $-689.5M | $-487.2M | $-258.3M | $-188.0M | $-110.7M | $-54.1M | $-40.3M |
| Operating Margin | — | — | -4,207.1% | -730.0% | -639.7% | -257.5% | -108.2% | -200.0% |
| Interest Expense | — | — | — | $0 | $12.0K | $71.0K | $106.0K | $116.0K |
| Pretax Income | $-1.13B | $-600.8M | $-439.9M | $-249.1M | $-187.1M | $-108.5M | $-52.0M | $-41.8M |
| Income Tax Expense | $0 | $-753.0K | $-3.5M | $-420.0K | $0 | $-371.0K | $-4.4M | — |
| Net Income | $-1.13B | $-600.1M | $-436.4M | $-248.7M | $-187.1M | $-108.2M | $-47.7M | $-41.8M |
| Net Margin | — | — | -3,768.3% | -703.0% | -636.6% | -251.6% | -95.2% | -207.2% |
| EPS (Basic) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 | $-22.33 | $-21.24 |
| EPS (Diluted) | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 | $-22.33 | $-21.24 |
| Shares Outstanding (Basic) | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 54.9M | 3.3M | — |
| Shares Outstanding (Diluted) | 190.1M | 167.7M | 113.1M | 80.6M | 72.8M | 54.9M | 3.3M | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |